252 related articles for article (PubMed ID: 31555286)
1. Altered Expression of Complement Regulatory Proteins CD35, CD46, CD55, and CD59 on Leukocyte Subsets in Individuals Suffering From Coronary Artery Disease.
Mishra N; Mohata M; Narang R; Lakshmy R; Hazarika A; Pandey RM; Das N; Luthra K
Front Immunol; 2019; 10():2072. PubMed ID: 31555286
[TBL] [Abstract][Full Text] [Related]
2. Early expression changes of complement regulatory proteins and C5A receptor (CD88) on leukocytes after multiple injury in humans.
Amara U; Kalbitz M; Perl M; Flierl MA; Rittirsch D; Weiss M; Schneider M; Gebhard F; Huber-Lang M
Shock; 2010 Jun; 33(6):568-75. PubMed ID: 19864971
[TBL] [Abstract][Full Text] [Related]
3. Use of complement regulators, CD35, CD46, CD55, and CD59, on leukocytes as markers for diagnosis of viral and bacterial infections.
Nuutila J; Jalava-Karvinen P; Hohenthal U; Kotilainen P; Pelliniemi TT; Nikoskelainen J; Lilius EM
Hum Immunol; 2013 May; 74(5):522-30. PubMed ID: 23376460
[TBL] [Abstract][Full Text] [Related]
4. Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.
Dzietczenia J; Wróbel T; Mazur G; Poreba R; Jaźwiec B; Kuliczkowski K
Med Oncol; 2010 Sep; 27(3):743-6. PubMed ID: 19662541
[TBL] [Abstract][Full Text] [Related]
5. Different expression and mobilisation of the complement regulatory proteins CD35, CD55 and CD59 in neonatal and adult neutrophils.
Lothian C; Dahlgren C; Lagercrantz H; Lundahl J
Biol Neonate; 1997; 72(1):15-21. PubMed ID: 9313830
[TBL] [Abstract][Full Text] [Related]
6. HBXIP upregulates CD46, CD55 and CD59 through ERK1/2/NF-κB signaling to protect breast cancer cells from complement attack.
Cui W; Zhao Y; Shan C; Kong G; Hu N; Zhang Y; Zhang S; Zhang W; Zhang Y; Zhang X; Ye L
FEBS Lett; 2012 Mar; 586(6):766-71. PubMed ID: 22293503
[TBL] [Abstract][Full Text] [Related]
7. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
Weng WK; Levy R
Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
[TBL] [Abstract][Full Text] [Related]
8. Diminished expression of complement regulatory proteins on peripheral blood cells from systemic lupus erythematosus patients.
Alegretti AP; Schneider L; Piccoli AK; Monticielo OA; Lora PS; Brenol JC; Xavier RM
Clin Dev Immunol; 2012; 2012():725684. PubMed ID: 22761633
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.
Thielen AJF; van Baarsen IM; Jongsma ML; Zeerleder S; Spaapen RM; Wouters D
J Immunol Methods; 2018 May; 456():15-22. PubMed ID: 29447841
[TBL] [Abstract][Full Text] [Related]
10. Antibodies to complement regulatory proteins.
Daniels G; Green C; Petty A
Transfus Clin Biol; 1997; 4(1):127-9. PubMed ID: 9095518
[No Abstract] [Full Text] [Related]
11. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement.
Jurianz K; Ziegler S; Donin N; Reiter Y; Fishelson Z; Kirschfink M
Int J Cancer; 2001 Sep; 93(6):848-54. PubMed ID: 11519047
[TBL] [Abstract][Full Text] [Related]
12. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
[TBL] [Abstract][Full Text] [Related]
13. Coordinator's report: complement regulatory proteins.
Moulds JM; Blanchard D; Daniels G; Flegel W; Hadley A; Medof ME; Ribera A
Transfus Clin Biol; 1997; 4(1):117-9. PubMed ID: 9095515
[No Abstract] [Full Text] [Related]
14. Anaemia & expression levels of CD35, CD55 & CD59 on red blood cells in Plasmodium falciparum malaria patients from India.
Mahajan RC; Narain K; Mahanta J
Indian J Med Res; 2011 Jun; 133(6):662-4. PubMed ID: 21727667
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
[TBL] [Abstract][Full Text] [Related]
16. Complement regulatory proteins in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Cheng L; Gou SJ; Qiu HY; Ma L; Fu P
Clin Exp Immunol; 2018 Jan; 191(1):116-124. PubMed ID: 28940198
[TBL] [Abstract][Full Text] [Related]
17. Complement regulatory proteins of human and non-human primates.
Moulds JM; Wells TD
Transfus Clin Biol; 1997; 4(1):121-3. PubMed ID: 9095516
[No Abstract] [Full Text] [Related]
18. Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies.
Guc D; Canpinar H; Kucukaksu C; Kansu E
Eur J Haematol; 2000 Jan; 64(1):3-9. PubMed ID: 10680700
[TBL] [Abstract][Full Text] [Related]
19. Expression levels of CD47, CD35, CD55, and CD59 on red blood cells and signal-regulatory protein-alpha,beta on monocytes from patients with warm autoimmune hemolytic anemia.
Barros MM; Yamamoto M; Figueiredo MS; Cançado R; Kimura EY; Langhi DM; Chiattone CS; Bordin JO
Transfusion; 2009 Jan; 49(1):154-60. PubMed ID: 18954403
[TBL] [Abstract][Full Text] [Related]
20. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
Golay J; Lazzari M; Facchinetti V; Bernasconi S; Borleri G; Barbui T; Rambaldi A; Introna M
Blood; 2001 Dec; 98(12):3383-9. PubMed ID: 11719378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
